Lv6
2400 积分 2021-09-11 加入
Impact of effective dose to immune cells (EDIC) on lymphocyte nadir and survival in limited-stage SCLC
2天前
已完结
Silver Jubilee of HER2 targeting: a clinical success in breast cancer
3天前
已完结
Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer
4天前
已完结
Expanding the Spectrum of NUTM1-Rearranged Sarcoma
4天前
已完结
Oncolytic virus VG161 in refractory hepatocellular carcinoma
6天前
已完结
A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma
7天前
已完结
Subsequent Survival and Loss of Lifetime for Patients With Progression‐Free 24 Months After Treatment in Nasopharyngeal Carcinoma: A Comprehensive Nationwide Population‐Based Analysis
9天前
已完结
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials
10天前
已完结
Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion–Positive Lung Cancer by Combining Selpercatinib with Crizotinib
10天前
已完结
Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion–Positive Lung Cancer by Combining Selpercatinib with Crizotinib
10天前
已完结
皖公网安备34019202002308
